HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Comparison of antioxidant and nonantioxidant lipoxygenase inhibitors on neutrophil function. Implications for pathogenesis of myocardial reperfusion injury.

Abstract
The activation and accumulation of leukocytes during inflammatory processes such as that initiated by myocardial ischemia and reflow appear to be major determinants of irreversible tissue injury. Myocardial salvage by dual cyclooxygenase/lipoxygenase inhibitors and selective 5-lipoxygenase inhibitors has suggested a role for lipoxygenase (LOX) products, such as the potent chemotactic factor leukotriene B4, in ischemia-reflow injury. However, many LOX inhibitors are antioxidants and several have been shown to directly inhibit neutrophil function in vitro, thereby questioning the role of LOX products in reperfusion injury. To clarify further the protective mechanism of lipoxygenase inhibitors, we have examined the effects of two nonantioxidant inhibitors, SK&F 86002 and REV-5901, on human neutrophil activation and function in vitro. The antioxidant LOX inhibitor nordihydroguiaretic acid, which served as a positive control, exhibited a concentration-dependent inhibition of N-formyl-methionyl-leucyl-phenylalanine (fMLP) and recombinant C5a-induced neutrophil bipolarization, fMLP-induced upregulation of the adherence glycoprotein Mac-1 (CD11b/CD18), fMLP-induced aggregation and neutrophil adherence to and migration through interleukin-1-stimulated human endothelial monolayers. In contrast, neither SK&F 86002 nor REV-5901 (in concentrations up to 50 microM) had any effect on these functions, nor did they inhibit neutrophil oxidative metabolism (phorbol myristate acetate-induced chemiluminescence). Inasmuch as both of these agents have been observed to reduce myocardial ischemia-reflow injury in vivo, their failure to directly inhibit neutrophil function further supports an important role for chemotactic LOX products in the pathogenesis of reperfusion injury.
AuthorsS B Shappell, A A Taylor, H Hughes, J R Mitchell, D C Anderson, C W Smith
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 252 Issue 2 Pg. 531-8 (Feb 1990) ISSN: 0022-3565 [Print] UNITED STATES
PMID2156049 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antigens, Differentiation
  • Antioxidants
  • Hydroxyquinolines
  • Imidazoles
  • Lipoxygenase Inhibitors
  • Macrophage-1 Antigen
  • Quinolines
  • Receptors, Leukocyte-Adhesion
  • Thiazoles
  • alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol
  • Leukotriene B4
  • N-Formylmethionine Leucyl-Phenylalanine
  • 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole
  • Masoprocol
Topics
  • Antigens, Differentiation (analysis)
  • Antioxidants (pharmacology)
  • Cell Aggregation (drug effects)
  • Cell Movement (drug effects)
  • Humans
  • Hydroxyquinolines (pharmacology)
  • Imidazoles (pharmacology)
  • Leukotriene B4 (biosynthesis)
  • Lipoxygenase Inhibitors
  • Macrophage-1 Antigen
  • Masoprocol (pharmacology)
  • Myocardial Reperfusion Injury (etiology, prevention & control)
  • N-Formylmethionine Leucyl-Phenylalanine (pharmacology)
  • Neutrophils (drug effects, metabolism)
  • Quinolines
  • Receptors, Leukocyte-Adhesion (analysis)
  • Thiazoles (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: